Theranostics 2019; 9(23):6885-6900. doi:10.7150/thno.36510 This issue Cite

Review

Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery

Da Sun1,2*, Jia Chen3*, Yuan Wang4, Hao Ji1, Renyi Peng1, Libo Jin1,2✉, Wei Wu1,5✉

1. Institute of Life Sciences, Wenzhou University, Wenzhou, 325035, China.
2. Biomedical Collaborative Innovation Center of Zhejiang Province & Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Biomedical Collaborative Innovation Center of Wenzhou, Wenzhou, Zhejiang, 325035, China.
3. Sichuan Provincial Center for Mental Health, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, 610072, China.
4. Chongqing Business Vocational College, Chongqing, 401331, China.
5. Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China.
*These authors contributed equally to this work.

Citation:
Sun D, Chen J, Wang Y, Ji H, Peng R, Jin L, Wu W. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Theranostics 2019; 9(23):6885-6900. doi:10.7150/thno.36510. https://www.thno.org/v09p6885.htm
Other styles

File import instruction

Abstract

Graphic abstract

Cancer remains a daunting and cureless disease, which is responsible for one-sixth of human deaths worldwide. These mortality rates have been expected to rise in the future due to the side effects of conventional treatments (chemotherapy, radiotherapy, and surgery), which can be addressed by applying nanomedicine. In order to escape from biological barriers, such nanomedicine should be mimicked and designed to be stealthy while navigating in the bloodstream. To achieve this, scientists take advantage of erythrocytes (red blood cells; RBCs) as drug carriers and develop RBC membrane (RBCm) coating nanotechnology. Thanks to the significant advances in nanoengineering, various facile surface functionalization methods can be applied to arm RBCm with not only targeting moieties, but also imaging agents, therapeutic agents, and nanoparticles, which are useful for theranostic nanomedicine. This review focuses on refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.

Keywords: erythrocytes, nanomedicine, refunctionalization, cancer


Citation styles

APA
Sun, D., Chen, J., Wang, Y., Ji, H., Peng, R., Jin, L., Wu, W. (2019). Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Theranostics, 9(23), 6885-6900. https://doi.org/10.7150/thno.36510.

ACS
Sun, D.; Chen, J.; Wang, Y.; Ji, H.; Peng, R.; Jin, L.; Wu, W. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Theranostics 2019, 9 (23), 6885-6900. DOI: 10.7150/thno.36510.

NLM
Sun D, Chen J, Wang Y, Ji H, Peng R, Jin L, Wu W. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Theranostics 2019; 9(23):6885-6900. doi:10.7150/thno.36510. https://www.thno.org/v09p6885.htm

CSE
Sun D, Chen J, Wang Y, Ji H, Peng R, Jin L, Wu W. 2019. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Theranostics. 9(23):6885-6900.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.